Chen Han, Yang Bi-wei, Yuan Man, Tang Hong, Bai Lang, Liu Cong, He Min, Wang Li-chun
Sichuan Da Xue Xue Bao Yi Xue Ban. 2016 Mar;47(2):197-202.
To investigate the prevention and therapeutic effects of Fuzheng Huayu Capsule on liver fibrosis in rats and its possible mechanism by regulating the expression of connective tissue growth factor (CTGF).
Forty Wistar rats were randomly divided into five groups: the normal group, the preventive group (the preventive experimental group and the preventive control group) and the treatment group (the treatment experimental group and the treatment control group). All the rats, except those in the normal group, were given CCl4 by subcutaneous injection and alcohol by oral adminstration to establish the model of liver fibrosis; meanwhile the rats in normal group were given same amount of olive oil by subcutaneous injection and water by oral administration. The preventive experimental group and control group were treated with Fuzheng Huayu crude drug 0.46 g/kg body mass through stomach irrigation and saline respectively once a day for four weeks during the modeling process. The treatment experimental group and control group were treated with Fuzheng Huayu crude drug 0.46 g/kg body mass through stomach irrigation and saline respectively once a day for four weeks after the modeling process. Blood was collected for the examination of liver function and serum fibrosis marker. HE staining was used to examine the pathological changes in liver tissue. The expression of CTGF was detected by immunohistochemistry.
Compared with the preventive experimental group, total bilirubin (TB), alanine aminotransferase (ALT) and hyaluronic acid (HA) in the preventive control group decreased significantly (P < 0.05). Compared with the treatment control group, ALT and laminin (LN) in the treatment experimental group decreased significantly (P < 0.01). Compared with the treatment comtrol group, the inflammation and hepatic fibrosis in the treatment experimental group alleviated significantly. The expression of CTGF in the treatment experimental group were significantly lower than that in the treatment control group (P < 0.05).
Fuzheng Huayu Capsule showed the prevention and therapeutic effects on experimental liver fibrosis. Meanwhile, Fuzheng Huayu Capsule could inhibit the CTGF expression in liver tissue, which may be one of the molecular mechanisms of these effects.
探讨扶正化瘀胶囊对大鼠肝纤维化的防治作用及其通过调节结缔组织生长因子（CTGF）表达发挥作用的可能机制。
将40只Wistar大鼠随机分为五组：正常组、预防组（预防实验组和预防对照组）和治疗组（治疗实验组和治疗对照组）。除正常组大鼠外，其余大鼠均皮下注射四氯化碳并灌胃给予乙醇以建立肝纤维化模型；同时正常组大鼠皮下注射等量橄榄油并灌胃给予水。在造模过程中，预防实验组和对照组分别每天经胃灌胃给予扶正化瘀生药0.46 g/kg体重和生理盐水，持续四周。造模后，治疗实验组和对照组分别每天经胃灌胃给予扶正化瘀生药0.46 g/kg体重和生理盐水，持续四周。采集血液检测肝功能及血清纤维化标志物。采用苏木精-伊红（HE）染色观察肝组织病理变化。采用免疫组化法检测CTGF的表达。
与预防实验组相比，预防对照组总胆红素（TB）、丙氨酸氨基转移酶（ALT）和透明质酸（HA）显著降低（P < 0.05）。与治疗对照组相比，治疗实验组ALT和层粘连蛋白（LN）显著降低（P < 0.01）。与治疗对照组相比，治疗实验组炎症及肝纤维化明显减轻。治疗实验组CTGF表达明显低于治疗对照组（P < 0.05）。
扶正化瘀胶囊对实验性肝纤维化具有防治作用。同时，扶正化瘀胶囊可抑制肝组织中CTGF的表达，这可能是其发挥这些作用的分子机制之一。
